Literature DB >> 21127977

Correlation of C-reactive protein with clinical and endoscopic activity in patients with ulcerative colitis.

Sami Karoui1, Sonia Laz, Meriem Serghini, Norsaf Bibani, Jalel Boubaker, Azza Filali.   

Abstract

BACKGROUND AND AIMS: Evaluating disease activity is important in ulcerative colitis. Laboratory markers should be a non-invasive alternative to endoscopy for patients. The objective of our study was to scrutinize the correlation between C-reactive protein (CRP) levels and clinical and endoscopic activity in ulcerative colitis patients.
MATERIALS AND METHODS: We conducted a prospective study between January 2007 and December 2009. In the study we chose consecutive patients of our department with ulcerative colitis. All patients received a standardized questionnaire, clinical examination, and colonoscopy. Based on clinical and endoscopic data, we calculated the disease activity index (DAI) and the Rachmilewitz score.
RESULTS: One-hundred and one patients were included. At the time of inclusion, 67 patients had an active disease and 34 patients were in remission. The mean DAI was 6.9 (1-12). The mean Rachmilewitz score was 4.7 (0-12). The median CRP rate was 20.2 ± 24.5 mg/l (1-107 mg/l). An increased CRP was found in 46 patients (46%). An increased CRP level was observed in patients with active disease (P < 0.0001). The DAI was higher in patients with increased CRP (9.5 ± 1.6 vs. 4.7 ± 3.6; P < 0.0001). The Rachmilewitz score was also higher in patients with increased CRP (7.2 ± 2.3 vs. 2.7 ± 3.2; P < 0.0001). A statistically significant association was found between the CRP and the DAI (r = 0.51, P < 0.0001) and between the CRP and the Rachmilewitz score (r = 0.46, P < 0.0001). The optimum cut-off of CRP level that separates active or inactive disease was calculated to be 10 ml/l, with AUC estimated at 0.81 ± 0.04 (95%CI: 0.72-0.88), a sensitivity of 67.1 (95%CI: 54.6-78.1) and a specificity of 97% (95%CI: 84.6-99.5).
CONCLUSION: Levels of CRP are correlated to clinical and endoscopic activity in ulcerative colitis patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21127977     DOI: 10.1007/s10620-010-1496-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  15 in total

1.  C-reactive protein reassessed.

Authors:  Alan R Tall
Journal:  N Engl J Med       Date:  2004-04-01       Impact factor: 91.245

2.  European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis.

Authors:  E F Stange; S P L Travis; S Vermeire; W Reinisch; K Geboes; A Barakauskiene; R Feakins; J F Fléjou; H Herfarth; D W Hommes; L Kupcinskas; P L Lakatos; G J Mantzaris; S Schreiber; V Villanacci; B F Warren
Journal:  J Crohns Colitis       Date:  2008-01-18       Impact factor: 9.071

3.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.

Authors:  Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren
Journal:  Can J Gastroenterol       Date:  2005-09       Impact factor: 3.522

4.  Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.

Authors:  Jost Langhorst; Sigrid Elsenbruch; Julia Koelzer; Andreas Rueffer; Andreas Michalsen; Gustav J Dobos
Journal:  Am J Gastroenterol       Date:  2007-10-04       Impact factor: 10.864

5.  Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease.

Authors:  Craig A Solem; Edward V Loftus; William J Tremaine; William S Harmsen; Alan R Zinsmeister; William J Sandborn
Journal:  Inflamm Bowel Dis       Date:  2005-08       Impact factor: 5.325

6.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.

Authors:  K W Schroeder; W J Tremaine; D M Ilstrup
Journal:  N Engl J Med       Date:  1987-12-24       Impact factor: 91.245

7.  Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.

Authors:  D Rachmilewitz
Journal:  BMJ       Date:  1989-01-14

Review 8.  C-reactive protein as a marker for inflammatory bowel disease.

Authors:  Séverine Vermeire; Gert Van Assche; Paul Rutgeerts
Journal:  Inflamm Bowel Dis       Date:  2004-09       Impact factor: 5.325

9.  Correlations among total colonoscopic findings, clinical symptoms, and laboratory markers in ulcerative colitis.

Authors:  Taro Osada; Toshifumi Ohkusa; Isao Okayasu; Tsutomu Yoshida; Shu Hirai; Kazuko Beppu; Tomoyoshi Shibuya; Naoto Sakamoto; Osamu Kobayashi; Akihito Nagahara; Takeshi Terai; Sumio Watanabe
Journal:  J Gastroenterol Hepatol       Date:  2008-12       Impact factor: 4.029

Review 10.  Laboratory markers in IBD: useful, magic, or unnecessary toys?

Authors:  S Vermeire; G Van Assche; P Rutgeerts
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

View more
  19 in total

1.  Neutrophil-to-lymphocyte ratio has a close association with gangrenous appendicitis in patients undergoing appendectomy.

Authors:  Mitsuru Ishizuka; Takayuki Shimizu; Keiichi Kubota
Journal:  Int Surg       Date:  2012 Oct-Dec

2.  How useful are blood and stool biomarkers for detecting subclinical mucosal inflammation in ulcerative colitis?

Authors:  Byong Duk Ye
Journal:  Dig Dis Sci       Date:  2014-01-17       Impact factor: 3.199

3.  Correlation of Hypoxia-inducible facto-1α and C-reactive protein with disease evaluation in patients with ulcerative colitis.

Authors:  Shuxia Yu; Bin Li; Jinghua Hao; Xiuju Shi; Jian Ge; Hongwei Xu
Journal:  Am J Transl Res       Date:  2020-12-15       Impact factor: 4.060

Review 4.  C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis.

Authors:  Mahmoud H Mosli; Guangyong Zou; Sushil K Garg; Sean G Feagan; John K MacDonald; Nilesh Chande; William J Sandborn; Brian G Feagan
Journal:  Am J Gastroenterol       Date:  2015-05-12       Impact factor: 10.864

5.  Comparison between quantitative assessment of bowel wall vascularization by contrast-enhanced ultrasound and results of histopathological scoring in ulcerative colitis.

Authors:  Christiane Girlich; Doris Schacherer; Ernst Michael Jung; Frank Klebl; Elisabeth Huber
Journal:  Int J Colorectal Dis       Date:  2011-08-17       Impact factor: 2.571

6.  Does neutrophil-to-lymphocyte ratio predict active ulcerative colitis?

Authors:  Emrah Posul; Bulent Yilmaz; Gulali Aktas; Mevlut Kurt
Journal:  Wien Klin Wochenschr       Date:  2015-01-10       Impact factor: 1.704

7.  C-reactive protein is superior to fecal biomarkers for evaluating colon-wide active inflammation in ulcerative colitis.

Authors:  Natsuki Ishida; Tomohiro Higuchi; Takahiro Miyazu; Satoshi Tamura; Shinya Tani; Mihoko Yamade; Moriya Iwaizumi; Yasushi Hamaya; Satoshi Osawa; Takahisa Furuta; Ken Sugimoto
Journal:  Sci Rep       Date:  2021-06-14       Impact factor: 4.379

8.  Matrix metalloproteinase-9: its interplay with angiogenic factors in inflammatory bowel diseases.

Authors:  Malgorzata Matusiewicz; Katarzyna Neubauer; Magdalena Mierzchala-Pasierb; Andrzej Gamian; Malgorzata Krzystek-Korpacka
Journal:  Dis Markers       Date:  2014-03-31       Impact factor: 3.434

Review 9.  Advances in the diagnosis and management of inflammatory bowel disease: challenges and uncertainties.

Authors:  Mahmoud Mosli; Mohammad Al Beshir; Bandar Al-Judaibi; Turki Al-Ameel; Abdulaziz Saleem; Talat Bessissow; Subrata Ghosh; Majid Almadi
Journal:  Saudi J Gastroenterol       Date:  2014 Mar-Apr       Impact factor: 2.485

10.  Correlation between Histological Activity and Endoscopic, Clinical, and Serologic Activities in Patients with Ulcerative Colitis.

Authors:  Dae Bum Kim; Kang-Moon Lee; Ji Min Lee; Yoon Yung Chung; Hea Jung Sung; Chang Nyol Paik; Woo Chul Chung; Ji-Han Jung; Hyun Joo Choi
Journal:  Gastroenterol Res Pract       Date:  2015-12-29       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.